INTRODUCTION
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children and adolescents and is a leading cause of cancer-related deaths in these patients (1) . Current clinical practices have had only minimal impact on cure for patients with resistant phenotypes or after relapse (2, 3) . A number of ALL phenotypes exhibit mutations that lead to inactivation or constitutive activation of oncogenic pathways such as LKB1, PTEN, PI3K/Akt and RAS, which have been linked to the regulation of energy metabolism in general, and glucose metabolism in particular (4) (5) (6) . T-ALL is known to have a high rate of PTEN mutations that lead to constitutive activation of Akt (7) . Our laboratory has previously demonstrated that the master energy regulator AMPK has significant feed-forward and feedback crosstalk with these pathways and that AMPK is a suitable target for ALL therapy (8, 9) . Consequently, although targeting glucose metabolism in ALL has not been explored, the above-described biology of ALL lymphoblasts suggests a significant therapeutic potential.
The increased glycolytic rate exhibited by cancer cells compared to their nonmalignant counterparts, even in the presence of sufficient oxygen, was first described by Otto H. Warburg (10) . This unique alteration in glucose metabolism provides a biochemical basis for targeting glycolysis as a selective anticancer treatment strategy.
Indeed, the glucose analogue 2-deoxy-D-glucose (2-DG) has shown activity against solid tumors in pre-clinical models and early phase human clinical trials (11) , but its role as an anti-leukemic agent has not been explored. 2-DG can induce cell growth arrest and cell death by inhibiting two key glycolytic enzymes, hexokinase (HK) and phosphoglucose isomerase (PGI) (12) 2-DG induces UPR-mediated cell death in ALL 4 transporters, 2-DG is converted to 2-DG-6-phosphate by HK, but unlike glucose-6-phosphate, 2-DG-6-phosphate cannot be further metabolized by PGI, and its accumulation inhibits the glycolytic pathway (13) . Inhibition of glycolysis has been demonstrated to be a main mechanism of 2-DG's cytotoxicity in hypoxic cells of solid tumors (14) . However, due to its structural similarity with mannose, 2-DG has also been shown to be a potent inhibitor of N-linked glycosylation (12, 15) . Indeed, 2-DG can be incorporated in place of mannose into lipid-linked oligosaccharide (LLO) chains (15) , but unlike mannose, 2-DG cannot accommodate the required complex branching structure of these molecules, leading to premature termination of LLO synthesis, and accumulation of misfolded, nascent ER-synthesized proteins (16).
The 2-DG-induced accumulation of misfolded glycoproteins in the ER lumen leads to ER stress and induction of the UPR, a protective physiologic response aimed at reducing the presence of unfolded proteins and consequently ER stress (11, 12) . The UPR is mediated via three ER transmembrane receptors: protein kinase dsRNA-like ER kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1α (IRE1α), which are activated upon dissociation from the main ER chaperone protein GRP78 to fully engage the UPR (17) . In addition to its role in the removal of excess misfolded proteins from the ER lumen for proteosomal degradation, GRP78 also functions to suppress pro-apoptotic pathways triggered by ER stress (18) . However, the protective capacity of the UPR is limited, and prolonged ER stress will eventually trigger irreversible pro-apoptotic signals such as increased expression of CHOP (CCAAT/enhancer binding protein homologous transcriptional factor) (19) . In most malignant cell types, CHOP induction is considered sufficient to induce ER stress/UPR- 2-DG induces UPR-mediated cell death in ALL 5 mediated cell death, whereas in B-lineage lymphocytes, apoptotic death is determined by the homeostatic balance between multiple UPR proteins rather than changes in any single UPR protein (20) .
In this study, due to the dual nature of 2-DG as an inhibitor of glycolysis and an inducer of ER stress, we evaluated its effects on these pathways in B-precursor and T-cell ALL cell models and primary cells. These studies uncovered that unlike most cancer phenotypes, which do not undergo cell death when treated with relatively low doses (<8mM) of 2-DG under normoxic as opposed to hypoxic conditions, ALL cells undergo apoptosis primarily through activation of ER stress. Moreover, we found differential sensitivity to inhibition of N-linked glycosylation vs. aerobic glycolysis within ALL subtypes, where Bp-ALL cells show significantly greater sensitivity to 2-DG than T-ALL cells. We demonstrated that the decreased sensitivity of T-ALL is conferred by Akt, and consequently co-targeting Akt signaling enhances cell death in 2-DG treated ALL cells.
Finally, we establish that Akt and AMPK differentially modulate the ability of ALL cells to effectively activate UPR, which buffers the pro-apoptotic effects of 2-DG-induced glycoprotein misfolding and ER stress. 
MATERIAL AND METHODS

Cell culture and reagents
The ALL cell lines CCRF-CEM (T-ALL), Jurkat (T-ALL), and NALM6 (B precursor-ALL) were maintained in RPMI 1640 medium (Cellgro, Manassas, VA) supplemented with 10% heat-inactivated FBS (Sigma-Aldrich, St. Louis, MO) and antibiotics (penicillin, 100 I.U./ml; streptomycin, 100 µg/ml) (Cellgro). SupB15 cells 
Cell viability and apoptosis assays
Cell viability was assayed by trypan blue exclusion using the Vi-CELL XR analyzer (Beckman Coulter, Brea, CA). Cell death was determined either using the Vi-CELL XR or by flow cytometry analysis of Annexin V-FITC/propidium iodide (PI) staining using BD Pharmigen FITC Annexin V apoptosis detection kit (CA, USA). (21) . Statistical differences in cell proliferation or cell death were assessed by one-way ANOVA followed by the Newman-Keuls multiple comparison test, or by unpaired Student's t test using GraphPad PRISM (San Diego, CA).
Construction of stable shRNA-expressing cell lines
To down-regulate the expression of Akt1 and GRP78, we used lentiviral particles generated from co-transfection of p8.2vpdeltaR, pVSVG-pseudotyped lentiviral and 2-DG induces UPR-mediated cell death in ALL 8 and selection with 1 µg/ml puromycin as described elsewhere (24) . Each stable shRNAexpressing cell line was validated for knockdown by immunoblotting.
Protein extracts and Immunoblots
Cells were harvested at the specified time points, washed with 1X PBS, and sonicated in 50 mM Tris-HCl (pH 7.4) containing protease inhibitors (Thermo). Proteins 2-DG induces UPR-mediated cell death in ALL 10 linked glycosylation (12, 14) . D-mannose has been shown to reverse both the growth inhibitory and cytotoxic effects associated with inhibition of N-linked glycosylation, but cannot reverse the cytotoxic effects triggered by inhibition of glycolysis (25, 26). In addition, 2-FDG is known to preferentially inhibit glycolysis with minimal effects on Nlinked glycosylation. Based on the profile of 2-DG and 2-FDG-induced cytotoxicity in ALL cells, we postulate that inhibition of N-linked glycosylation by 2-DG leads to cell death in T-ALL and although it appears to be the predominant mechanism leading to cytotoxicity in Bp-ALL, inhibition of glycolysis also contributes to cell death in the latter phenotype. Consequently, we co-treated CCRF-CEM, NALM6, and SupB15 cells with 2-DG and D-mannose, and evaluated the effects on cell death. Our results indicate that mannose completely reverses the cytotoxic effects of 2-DG in CCRF-CEM at 4 and 8 mM doses of 2-DG, but only at 4 mM 2-DG dose in NALM6 (Fig. 1D) . Partial reversal was seen in NALM6 at higher dose of 2-DG (8 mM) and in SupB15 cells at both doses (Fig. 1D ). Therefore inhibition of N-linked glycosylation is the predominant mechanism by which low-dose 2-DG induces cell death in ALL cells. However, phenotypic differences exist, and it is possible that in Bp-ALL, inhibition of aerobic glycolysis also contributes to 2-DG-induced cytotoxicity.
2-DG induces changes in the expression and phosphorylation/activation of Akt, AMPK and ER stress/UPR-associated signaling proteins in ALL cell lines
To further understand the molecular mechanisms by which 2-DG induces cell death in ALL, we examined the expression of critical signaling proteins associated with energy metabolism in general, glucose metabolism in particular, and cell proliferation. As 2-DG induces UPR-mediated cell death in ALL 11 shown in Figure 2A , 2-DG induced significant activation of P-AMPK (T172) in both cell lines. Consistent with increased P-AMPK expression, P-mTOR (S2448) and its downstream target P-p70S6K (T389) were down-regulated by 2-DG through the inhibitory effect of AMPK on mTOR activity (27) , and the downregulation of mTOR signaling was greater in NALM6 cells as compared to CCRF-CEM cells (Fig. 2A) . The PTEN-mutant CCRF-CEM cells exhibited both high basal expression and sustained increased expression of P-Akt (S473) (6 h vs. 24 h), whereas in NALM6 cells, the basal expression of P-Akt (S473) was lower and the strong upregulation of P-Akt (S473) observed at 6 h subsided by 24 h. Our data show a strong correlation between the high basal and sustained expression of P-Akt following treatment with 2-DG in CCRF-CEM cells and their relative resistance to this agent (Fig. 1B) . We postulate that PTEN 12 Akt/mTOR, and UPR signaling observed in these cell lines were replicated using representative primary ALL cells, validating their clinical relevance ( Fig. 2C; representative Bp-ALL sample). To confirm that the putative inhibition of N-linked glycosylation by 2-DG led to induction of ER stress/UPR, we treated the cell line models with 2-DG in the presence or absence of mannose. Western blots revealed that the addition of mannose (10 mM) resulted in downregulation of the UPR markers GRP78, PeIF2α (S51), and CHOP in both CCRF-CEM and NALM6 cells (Fig. 2D) , suggesting that mannose relieves ER stress-induced cytotoxicity in ALL cells by reversing 2-DGinduced inhibition of N-linked glycosylation.
Inhibition of Akt sensitizes ALL cells to 2-DG-induced cell death via a UPRmediated mechanism
Based on the upregulation of P-Akt (S473) in response to 2-DG and the relative resistance of cells, harboring inactivating PTEN mutations and constitutive activation of Akt, we hypothesized that Akt plays a central pro-survival role in ALL cells treated with 2-DG. To test this, we treated CCRF-CEM cells with a pharmacological inhibitor of Akt and examined its effects on 2-DG-mediated cell death. Figure 3A shows that inhibition of Akt signaling using the Akt inhibitor X (AIX, 10 µM), sensitized CCRF-CEM cells to even a very low dose of 2-DG (0.5 mM). This combination led to over 85% apoptotic death as compared to very modest effects with each agent alone ( Figure 3A ) (2-DG - 2-DG induces UPR-mediated cell death in ALL 13 analysis of CCRF-CEM cells treated with both agents (2-DG -0.5 and 10 mM; AIX -10 µM) showed significant downregulation of P-Akt (S473), and the UPR markers GRP78, IRE1α, P-eIF2α (S51), and CHOP, whereas the level of P-AMPK (T172) was significantly increased (Fig. 3B) .
To confirm these results, we used a genetic approach based on the lentiviral delivery of shRNAs to specifically knock down Akt1 expression in ALL cells. We found that shAkt1-expressing ALL cells treated with 2-DG (0.5, 1.5, and 5.0 mM) exhibited significant increase in apoptotic death compared to shRNA scramble controls (shSCR) (p<0.001 for CCRF-CEM; p<0.01 for NALM6) (Fig. 3C ). As expected, Western blotting showed downregulation of Akt1 in shAkt1-transduced cells compared to shSCR control cells. Moreover, as was the case in the AIX-treated cells, genetic downregulation of Akt lead to increased expression of P-AMPK (T172) and decreased expression of UPR markers IRE1α, GRP78, P-eIF2α (S51), and CHOP, compared to cells treated w 2-DG alone (Fig. 3D) . Taken together, our results demonstrate that Akt signaling is critical for ALL cell proliferation and survival in response to 2-DG treatment, and supports the role of Akt as a positive regulator of the pro-survival arm of the UPR (29) .
Inhibition of AMPK restores UPR function and rescues ALL cells from ER stressmediated cell death following treatment with 2-DG alone or in combination with
Akt downregulation
During the course of our investigations, we uncovered that 2-DG induced P-AMPK (T172) in ALL cells ( Fig. 2A) , and that inhibition of Akt further enhanced AMPK activation (Fig. 3) . To determine the role of AMPK in 2-DG treated ALL cells, we used 2-DG induces UPR-mediated cell death in ALL 14 shRNAs to down-regulate AMPKα1 in CCRF-CEM and NALM6 cells. Cells were treated with 2-DG (0.5 and 2.5 mM) ± AIX (10 µM), and the expression of AMPK, Akt, UPR markers, and cell death were examined. We found that downregulation of AMPK rescued CCRF-CEM and NALM6 cells from cell death induced by the combination of 2-DG + AIX ( Fig. 4A and 4B ; p<0.0001 and p<0.001 for shAMPK vs. shSCR cell death in CCRF-CEM and NALM6, respectively). Importantly, these effects were accompanied by increased induction of UPR markers in both AMPK knock-down cell lines treated with 2-DG + AIX ( Fig. 4C and 4D ), indicating that AMPK knock-down restored the ability of ALL cells to effectively engage the UPR.
Inhibition of GRP78 sensitizes ALL cells to 2-DG-induced cell death
To definitively establish that the ability of ALL cells to effectively engage the UPR is central to the ability of ALL cells to buffer 2-DG-induced cytotoxicity, we used a genetic approach to inhibit the main effector of UPR signaling -GRP78 (17, 18) and evaluated apoptotic death in 2-DG-treated ALL cells. Downregulation of GRP78 sensitized ALL cell models to equimolar concentrations of 2-DG, leading to a significant increase in cell death compared to shSCR-expressing cells (Fig. 5B, p<0 .001 for CCRF-CEM/shSCR vs. CCRF-CEM/shGRP78; Fig. 5C, p<0 .01 for NALM6/shSCR vs. NALM6/shGRP78). These data confirm that the ability of ALL cells to effectively engage the UPR is essential to buffer the pro-apoptotic effects of 2-DG. Recently it has been shown that ALL lymphoblasts exhibit increased glycolytic rate even in the presence of sufficient oxygen (34) . On this basis we examined the effects of targeting glucose metabolism, and found that unlike in most carcinomas, 2-DG induced significant apoptosis in ALL cell models and primary ALL cells under normoxic conditions. Nevertheless, phenotypic differences in sensitivity were seen between Bp-ALL and T-ALL, with the latter exhibiting relative resistance due to the hyperactivation of Akt signaling in this PTEN-mutant-prevalent phenotype. Most cancer phenotypes that exhibit resistance to 2-DG under normoxia, buffer the downstream pro-apoptotic signals induced by this glycolytic inhibitor by alternatively using other energy sources, fueling oxidative phosphorylation via the tricarboxylic acid cycle (TCA) to generate ATP (35, 36) . Therefore, our data suggest that ALL cells may be either unable to compensate via Bp-ALL, consistent with increased dependence on glycolysis by B-ALL than T-ALL cells (37) . Our data supports the notion that phenotypic differences in the regulation of glucose metabolism lead to the differential sensitivity of T-vs. Bp-ALL cells to 2-DG, and that further elucidation of these phenotypic differences may lead to lineage-specific therapeutic strategies.
Due to its structural similarity to mannose, a sugar central to N-linked glycosylation of proteins in the ER lumen, 2-DG can enter the glycosylation pathway and disrupt the elongation of polysaccharide chains linked to nascent proteins, resulting in accumulation of misfolded proteins in the ER lumen (12, 25) and induction of UPR (38) .
While the role of UPR is to alleviate sustained ER stress by inhibiting protein translation, activating chaperones and enhancing proteosomal degradation of misfolded proteins (17), the persistent ER stress will turn on the pro-apoptotic arm of UPR regulated by CHOP (19) . Our data indicate that 2-DG induces ALL cell death via a mechanism mediated by ER stress/UPR as evidenced by increased expression of several UPR markers, including 2-DG induces UPR-mediated cell death in ALL 18 DG-treated cells. It has been shown that Akt can negatively regulate AMPK activity in various cell models (47) (48) (49) and that AMPK can act as a suppressor of UPR activity (9) .
We propose that it is the inhibition of the pro-survival UPR response by AMPK, that significantly potentiates apoptosis in response to 2-DG treatment, rather than CHOPmediated apoptosis, induced in response to prolonged UPR and extensive ER stress.
Indeed, shRNA-mediated inhibition of AMPK rescued ALL cells from 2-DG-induced cytotoxicity, and correlated with restoration of the essential UPR signaling factors.
Therefore, restoration of effective UPR is needed for ALL cells to buffer and reduce the pro-apoptotic signals mediated by sustained 2-DG-induced ER stress. The pro-survival role of the UPR in determining the cellular response to 2-DG in ALL was further confirmed using shRNA inhibition of GRP78, which also sensitized ALL cells to 2-DG.
Based on these data we propose a model for the mechanism of 2-DG-induced cell death via ER stress/UPR-mediated apoptosis in which AMPK and Akt modulate the UPR (Fig. 
6)
In summary, we demonstrate for the first time that 2-DG (at low dose) induces cell death in ALL cells under normoxia by triggering ER stress/UPR-mediated apoptosis.
The sensitivity of ALL cells to 2-DG under normoxia places them among the few cancer phenotypes that behave this way, which is important when considering 2-DG as a potential anti-leukemic agent since leukemia cells circulate freely through normoxic and 2-DG interferes with N-linked glycosylation, leading to accumulation of misfolded glycoproteins, which triggers ER stress and induction of unfolded protein response (UPR). Binding of the misfolded glycoproteins to the central UPR regulator GRP78 will result in its dissociation from the UPR effectors (IRE1α, ATF6, and PERK), allowing them to fully engage UPR. GRP78 also acts a major chaperone during protein folding, removes excess misfolded proteins from the ER lumen for proteosomal degradation, and functions to suppress pro-apoptotic pathways triggered by CHOP. Separately, 2-DG inhibits glycolysis, decreases ATP levels and leads to activation of AMPK. Our data demonstrate that AMPK activation blocks expression of UPR signaling and significantly potentiates apoptosis in 2-DG treated ALL cells. Akt promotes UPR signaling and cell survival via downregulation AMPK. Therefore we hypothesize that it is the inhibition by AMPK of the pro-survival GRP78-mediated UPR signaling that significantly potentiates apoptosis in response to 2-DG plus AIX treatment, rather than the classical CHOPmediated apoptotic signaling induced by extensive ER stress and prolonged UPR. 
